

## Zealand announces the total number of shares and voting rights in the company as of 31 May 2016

*Copenhagen, 31 May 2016* - In accordance with Section 6 of the *Danish Statutory Order on Issuers' Disclosure Obligations*, Zealand announces the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Announcement no. 20 / 2016 dated 26 May 2016 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Zealand as of 31 May 2016.

Date	Total number of shares (nominal value of DKK 1 each)	Share capital (nominal value in DKK)	Total number of votes
31 May 2016	24,492,906	24,492,906	24,492,906



### For further information, please contact:

**Hanne Leth Hillman**, Senior Vice President, Investor Relations and Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

### About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a portfolio of products and projects under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-US) as Lyxumia<sup>®</sup> and has it under regulatory review in the US. The license agreement with Sanofi covers also a fixed-ratio combination of lixisenatide with basal insulin glargine (Lantus<sup>®</sup>) undergoing regulatory review in both the US and Europe.

Zealand's proprietary pipeline of product candidates includes: *ZP4207 (single-dose rescue treatment)* for acute, severe hypoglycemia (Phase II); *ZP1848* for Short Bowel Syndrome (Phase II); *ZP4207 (multiple-dose version)* for better hypoglycemia management in diabetes (Phase I); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: [www.zealandpharma.com](http://www.zealandpharma.com) or follow us on Twitter @ZealandPharma